(Q31032734)

29 September 2017

1 reference

title

Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder (English)

1 reference

obsessive-compulsive disorder

29 September 2017

1 reference

inferred from title

author

Christopher Pittenger

object named as

Christopher Pittenger

series ordinal

1

0 references

John Krystal

series ordinal

2

object named as

John H Krystal

1 reference

29 September 2017

Vladimir Coric

3

1 reference

PMC publication ID

3593363

29 September 2017

language of work or name

1 reference

1 January 2006

1 reference

29 September 2017

1 reference

29 September 2017

3

1 reference

29 September 2017

1

1 reference

29 September 2017

69-81

1 reference

Advances in the treatment of anxiety: targeting glutamate

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Finding what you are not looking for: strategies for developing novel treatments in psychiatry

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Deep brain stimulation for refractory obsessive-compulsive disorder

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

A multidimensional model of obsessive-compulsive disorder

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Extracellular metabolites in the cortex and hippocampus of epileptic patients

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

The role of venlafaxine in the treatment of obsessive-compulsive disorder

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

A review of the treatment for refractory obsessive-compulsive disorder: from medicine to deep brain stimulation

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Treatment of compulsive hoarding

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Neurosurgical interventions for neuropsychiatric syndromes

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes).

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Riluzole enhances glutamate uptake in rat astrocyte cultures

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Clinical practice. Obsessive-compulsive disorder

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

An open-label trial of riluzole in patients with treatment-resistant major depression

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Clinical studies implementing glutamate neurotransmission in mood disorders

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Obsessive-compulsive disorder: development of demand-controlled deep brain stimulation with methods from stochastic phase resetting

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Treatment non-response in OCD: methodological issues and operational definitions

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Refractory obsessive-compulsive disorder: state-of-the-art treatment

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

A review and meta-analysis of the genetic epidemiology of anxiety disorders

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Neuroprotective agent riluzole dramatically slows inactivation of Kv1.4 potassium channels by a voltage-dependent oxidative mechanism

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Brain anatomy and chemistry may predict treatment response in paediatric obsessive--compulsive disorder.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Symptom dimensions in obsessive-compulsive disorder: toward quantitative phenotypes

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Interaction of the neuroprotective drug riluzole with GABA(A) and glycine receptor channels

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Tourette's syndrome: when habit-forming systems form habits of their own?

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Toward a neurobiology of obsessive-compulsive disorder

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Effects of riluzole on electrically evoked neurotransmitter release

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Protection against glutamate-induced cytotoxicity in C6 glial cells by thiol antioxidants

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

On the track of cell survival pharmaceuticals in the oligodendrocyte type-2 astrocyte lineage.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

"Just right" perceptions associated with compulsive behavior in Tourette's syndrome

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms, and prevention.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Lifetime Prevalence of Specific Psychiatric Disorders in Three Sites

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Use of monochlorimipramine in psychiatric patients who are resistant to other therapy

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

The epidemiology of obsessive-compulsive disorder in five US communities.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Treatment of severe obsessive-compulsive disorder with fluvoxamine

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

The Yale-Brown Obsessive Compulsive Scale. II. Validity

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Biochemical considerations in1H spectroscopy. Glutamate and glutamine;Myo-inositol and related metabolites

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Distinct neural correlates of washing, checking, and hoarding symptom dimensions in obsessive-compulsive disorder.

14 July 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Mirtazapine plus citalopram has short term but not longer term benefits over citalopram alone for the symptoms of obsessive compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

A placebo-controlled trial of risperidone in Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Increased medial thalamic choline in pediatric obsessive-compulsive disorder as detected by quantitative in vivo spectroscopic imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Glutamatergic dysfunction in OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Altered cortical excitability in obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Riluzole augmentation for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURX.2005.12.006

Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Venlafaxine in treatment-resistant obsessive-compulsive disorder.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Magnetic resonance imaging-guided stereotactic limbic leukotomy for treatment of intractable psychiatric disease.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Proton magnetic resonance spectroscopy of lenticular nuclei in obsessive-compulsive disorder

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Rapid remission of OCD with tramadol hydrochloride.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

A short echo 1H spectroscopy and volumetric MRI study of the corpus striatum in patients with obsessive-compulsive disorder and comparison subjects

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

1H-magnetic resonance spectroscopy in obsessive-compulsive disorder: evidence for neuronal loss in the cingulate gyrus and the right striatum.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Obsessive-compulsive and spectrum disorders: overview and quality of life issues.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Use of anafranil (G 34586) in obsessive neuroses

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593363

Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline

25 November 2018

1 reference

12 December 2020

Visual Hallucinations from the Addition of Riluzole to Memantine and Bupropion

1 reference

12 December 2020

Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder

1 reference

12 December 2020

Association of temporal lobe epilepsy and obsessive-compulsive disorder in a patient successfully treated with right temporal lobectomy

1 reference

12 December 2020

Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder

1 reference

12 December 2020

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder

1 reference

12 December 2020

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

1 reference

12 December 2020

Treatment of obsessive-compulsive disorder: cognitive behavior therapy vs. exposure and response prevention

1 reference

12 December 2020

Pharmacotherapy for obsessive-compulsive disorder

1 reference

12 December 2020

Deep brain stimulation for psychiatric disorders

1 reference

12 December 2020

Modification of expectations in cases with obsessional rituals

1 reference

12 December 2020

Intravenous clomipramine for obsessive-compulsive disorder

1 reference

12 December 2020

Suppression of obsessive-compulsive symptoms after epilepsy surgery

1 reference

12 December 2020

Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine

1 reference

12 December 2020

Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress

1 reference

12 December 2020

Riluzole inhibits the persistent sodium current in mammalian CNS neurons

1 reference

12 December 2020

Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder

1 reference

12 December 2020

Proton spectroscopic imaging of the thalamus in treatment-naive pediatric obsessive-compulsive disorder

1 reference

12 December 2020

Evidence-based pharmacotherapy of obsessive-compulsive disorder

1 reference

12 December 2020

10.1016/J.NURX.2005.12.006

Identifiers

DOI

1 reference

29 September 2017

1 reference

PMC publication ID

3593363

29 September 2017

PubMed publication ID

16490414

1 reference

PMC publication ID

3593363